🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

.ESMO Open Analysis of phase III RCT ASCENT (n=509). Sacituzumab govitecan vs chemo in #mTNBC showed improved PFS across BMI subgroups (normal HR 0.48; overweight HR 0.31; obese HR 0.34) with manageable toxicity. PMID:40460679 pubmed.ncbi.nlm.nih.gov/40460679/

.ESMO Open Retrospective study (n=15) of patients with recurrence on adjuvant abemaciclib + ET for ER+/HER2- early BC. 50% had ER loss, 90% had P53 alterations, and the median duration of 1L metastatic treatment at relapse was 3 months. PMID:40466434 pubmed.ncbi.nlm.nih.gov/40466434/

Great work by Eva Blondeaux and colleagues 🇮🇹 published on ESMO Open!

.ESMO Open Phase III RCT PALLAS (n=4688) patient-reported outcomes. Palbociclib + ET vs ET alone in HR+/HER2− stage II-III #breastCancer. No clinically significant differences in patient-reported QoL or symptom severity. PMID:40472660 pubmed.ncbi.nlm.nih.gov/40472660/

.ESMO Open Prospective study (n=95). Tumor-agnostic methylation-based MRD (mMRD) for early-stage BC showed superior prognostic value (HR 17.0, P<0.0001) vs genomic MRD, with 62.5% sensitivity and 100% specificity for recurrence. PMID:40472659 pubmed.ncbi.nlm.nih.gov/40472659/

Real-world clinical outcomes of sacituzumab govitecan after prior exposure to enfortumab vedotin in pts with metastatic urothelial carcinoma in ESMO Open. In a large RW cohort, treatment with SG after prior EV resulted in limited clinical efficacy. esmoopen.com/article/S2059-…

Lenvatinib for patients with previously treated advanced thymic carcinoma in real-world settings in ESMO Open. RW data from Japan,107 pts, ORR 30% & mPFS 10.2 months; 64% G3 or higher AEs with 84% dose reduction & 23% discontinuation rates due to AEs. esmoopen.com/article/S2059-…

Financial toxicity and socioeconomic impact of cancer in Europe in ESMO Open. 66% of pts suffered from income loss (86% with additional treatment-related expenses), 16% delayed or avoided health services (medical visits, medications, surgery…). esmoopen.com/article/S2059-…

Pleased to report FGFR2b expression in gastric cancer and relationship with other biomarkers ESMO Open ESMO - Eur. Oncology. The results of bemarituzumab phase 3 studies are awaited.OncoAlert OncoDaily sciencedirect.com/science/articl…

This month Editor Spotlight ESMO Open is on Niccolò Bolli, Associate Professor of Hematology Università degli Studi di Milano, Milan. His research focuses on evolutionary aspects of MultipleMyeloma, prognostic genomics and drug sensitivity predictive markers. sciencedirect.com/journal/esmo-o…

Uncovering PD-L1 among immune cell predictive biomarkers and AGAs in anal squamous-cell carcinomas in the era of immunotherapy in ESMO Open. High PD-L1 expression (IHC>=2+ & >=5%) in 41.7%, any positivity associated with PIK3CA & CASP8 mutations. esmoopen.com/article/S2059-…

Association of KRAS variants with survival and therapeutic outcomes in biliary tract cancers in ESMO Open. KRASmutations occur in 23.4% of BTC, more frequent in intrahepatic & extrahepatic colangiocarcinoma, and associated with worse survival. esmoopen.com/article/S2059-…

What patients are eligible for adjuvant CDK4/6i? We looked at this in ConcertAI: the approval of ribo doubled the pts eligible for adjuvant CDK4/6i (15%➡️30%) and provided an option for 10% of pts with N0 disease, those with the most aggressive cancers. esmoopen.com/article/S2059-…

Pan-Asia adapted ESMO Clinical Practice Guideline for the management of patients with newly diagnosed and relapsed epithelial ovarian cancer in ESMO Open. Adapted recommendations for Asian patients to improve access to optimal cancer care via EBM. esmoopen.com/article/S2059-…

New study in ESMO Open examines clinicopathological features and genomics of ER-positive/HER2-negative #BreastCancer relapsing on adjuvant #abemaciclib. 🔓pubmed.ncbi.nlm.nih.gov/40466434/ ✍️Chiara Corti Daniel Abravanel, MD/PhD Paolo Tarantino G Curigliano MD PhD Tari King MD Dr. E Mittendorf Nancy Lin, MD Sara Tolaney

💊 Real-world lenvatinib in advanced thymic carcinoma (n=107, Japan): 🎯ORR 30%, mPFS 10.2 mo ❌G≥3 AEs 64%, 84% needed dose ⬇️, 23% d/c due to toxicity esmoopen.com/article/S2059-… 📉 Active, but at a price. Tame the thymus, but mind the toll. #ThymicCancer OncoAlert ESMO Open

T-DXd has shown tremendous activity in trials. But how does it perform in the real world? What is its activity in pts with BRCA+, PDL1+ dz, or prior SG? We joined forces with Yale University to address this question in one of the largest studies to date (n=~1500).🧵 esmoopen.com/article/S2059-…

Important report ESMO Open from Paolo Tarantino - real world outcomes with T-DXd show much shorter rwPFS in pts previously treated with sacituzumab govitecan. With so many ADCs now using topoisomerase inhibitors, can we truly sequence these drugs? esmoopen.com/article/S2059-…

Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a large real-world database of patients with metastatic breast cancer -ESMO Open esmoopen.com/article/S2059-…

Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trial☆ -ESMO Open esmoopen.com/article/S2059-…